Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALLR Allarity Therapeutics Inc

Trading 02-26 11:34:47 EST

1.00

+0.00

+0.01%

High1.04	Low0.9800	Vol34.59K
Open1.03	D1 Closing0.9999	Amplitude5.89%
Mkt Cap16.08M	Tradable Cap16.06M	Total Shares16.08M
T/O35.14K	T/O Rate0.22%	Tradable Shares16.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALLR","market":"US","secType":"STK","nameCN":"Allarity Therapeutics Inc","latestPrice":1,"timestamp":1772123589409,"preClose":0.9999,"halted":0,"volume":34586,"delay":0,"changeRate":0.000100010001000089,"floatShares":16056099,"shares":16080980,"eps":-1.334837,"marketStatus":"Trading","change":0.0001,"latestTime":"02-26 11:34:47 EST","open":1.03,"high":1.0389,"low":0.98,"amount":35138.871044399995,"amplitude":0.058906,"askPrice":1.01,"askSize":210,"bidPrice":1,"bidSize":258,"shortable":3,"etf":0,"ttmEps":-1.334837,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772139600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.9999,"preHourTrading":{"tag":"盘前","latestPrice":1.08,"preClose":0.9999,"latestTime":"08:32 EST","volume":1351,"amount":1458.8903196,"timestamp":1772112720211,"change":0.0801,"changeRate":0.080108,"amplitude":0.080008},"postHourTrading":{"tag":"盘后","latestPrice":1.01,"preClose":0.9999,"latestTime":"19:07 EST","volume":676,"amount":678.1872,"timestamp":1772064435743,"change":0.0101,"changeRate":0.010101,"amplitude":0.020102},"volumeRatio":0.616292},"requestUrl":"/m/hq/s/ALLR/tweets","defaultTab":"tweets","newsList":[{"id":"2612944501","title":"Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Relapsed SCLC Trial of Stenoparib Plus Temozolomide","url":"https://stock-news.laohu8.com/highlight/detail?id=2612944501","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612944501?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:15","pubTimestamp":1771420528,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. reported that the first patients have been dosed in a U.S. Department of Veterans Affairs-funded, investigator-initiated Phase 2 trial evaluating stenoparib , a dual PARP and WNT pathway inhibitor, in combination with temozolomide for relapsed small cell lung cancer. The study is open for enrollment across 11 VA medical centers in the United States. No clinical results were presented in the announcement; results are expected to be reported in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL15vmqR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","ALLR","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","LU2095319765.USD","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2612446649","title":"Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446649","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446649?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:15","pubTimestamp":1771420500,"startTime":"0","endTime":"0","summary":"Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240189/0/en/Allarity-Therapeutics-Doses-First-Patients-in-VA-Funded-Phase-2-Trial-Focused-on-Small-Cell-Lung-Cancer-with-High-Unmet-Need.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ALLR","BK4539","LENZ"],"gpt_icon":0},{"id":"2611908289","title":"Allarity Therapeutics Inc - Prospectus for Resale of 255,103 Shares of Common Stock by Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2611908289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611908289?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:38","pubTimestamp":1770932328,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z81NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLR","BK4139"],"gpt_icon":0},{"id":"2608987871","title":"Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide","url":"https://stock-news.laohu8.com/highlight/detail?id=2608987871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608987871?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:20","pubTimestamp":1770124833,"startTime":"0","endTime":"0","summary":"Allarity (ALLR) Therapeutics announced that enrollment is now open for its new Phase 2 clinical trial evaluating the combination of stenoparib and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/allarity-announce-enrollment-open-for-phase-2-trial-of-stenoparib-temozolomide-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/allarity-announce-enrollment-open-for-phase-2-trial-of-stenoparib-temozolomide-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALLR","BK4139"],"gpt_icon":0},{"id":"2608879859","title":"Allarity Therapeutics Announces That Its Collaborative Phase 2 Trial With the United States Veteran’s Administration Combining Stenoparib With Temozolomide in Relapsed Small Cell Lung Cancer Is NOW Open for Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879859?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123652,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ02Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"gpt_icon":0},{"id":"2608005876","title":"Allarity Therapeutics Partners with U.S. Department of Veterans Affairs for Phase 2 Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608005876","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608005876?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123629,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. has entered into a collaboration with the U.S. Department of Veterans Affairs  to conduct a Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer . The trial, fully funded by the VA's Special Emphasis Panel on Precision Oncology, is now open for enrollment at 11 VA sites across the United States. This partnership aims to explore the potential benefits and improved safety profile of stenoparib in combination regimens for patients with relapsed SCLC, particularly among veterans who have limited treatment options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL67nJML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","ALLR","LU2210149790.SGD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2607822790","title":"Allarity Therapeutics Inc - on Jan 28, Co Entered Stock Purchase Agreement With Tumim Stone Capital - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607822790","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607822790?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:50","pubTimestamp":1769691044,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU15O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"gpt_icon":0},{"id":"2607222082","title":"Allarity Therapeutics Inc - Company May Sell up to $6 Mln in Newly Issued Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607222082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607222082?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:50","pubTimestamp":1769691044,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU15O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"gpt_icon":0},{"id":"2595977115","title":"Allarity Therapeutics Advances Stenoparib Toward FDA Approval After Strategic Realignment","url":"https://stock-news.laohu8.com/highlight/detail?id=2595977115","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595977115?lang=en_us&edition=fundamental","pubTime":"2025-12-31 21:00","pubTimestamp":1767186016,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. issued a business update in a letter to shareholders from CEO Thomas H. Jensen. The company reported significant progress in 2025, highlighting the advancement of its lead asset, stenoparib—a dual PARP and WNT pathway inhibitor—toward FDA approval for advanced ovarian cancer. Allarity also broadened the potential indications for stenoparib, including its application in recurrent small cell lung cancer and other difficult-to-treat cancers. The company emphasized strengthened financial foundations and continued clinical development. Looking ahead to 2026, Allarity plans to accelerate stenoparib’s path to approval, expand its indications, and explore additional growth opportunities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL1d427w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4112","LU2095319765.USD","SG9999014005.SGD","ALLR","IE00B64PRP62.GBP","SG9999014021.USD","LU0314104364.USD","BK4139","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","BK4585"],"gpt_icon":0},{"id":"2593608415","title":"Allarity Therapeutics Raises $2.5 Million in Private Placement of Unregistered Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593608415","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593608415?lang=en_us&edition=fundamental","pubTime":"2025-12-23 22:22","pubTimestamp":1766499739,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. has announced the completion of an additional closing of a private placement with an accredited investor, selling 255,103 shares of common stock at $0.98 per share, raising approximately $250,000 in gross proceeds. This transaction is part of a previously disclosed Securities Purchase Agreement, under which the company had earlier sold 1,562,500 shares and/or pre-funded warrants for gross proceeds of about $2.5 million. The shares were sold in an unregistered offering, relying on an exemption from registration under Section 4 of the Securities Act. Allarity Therapeutics intends to use the net proceeds for general corporate purposes and working capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL3hBXP4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"gpt_icon":0},{"id":"2589098356","title":"Allarity Therapeutics Sets New CFO Compensation Package With $367,700 Salary and $160,000 RSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2589098356","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589098356?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:17","pubTimestamp":1765203445,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. has entered into a new employment agreement with Chief Financial Officer Jeffrey S. Ervin, effective December 3, 2025. Under the agreement, Ervin will serve as CFO on a full-time basis with an annual base salary of $367,700. He will also receive restricted stock units valued at $160,000, subject to time-based vesting, and is eligible for an annual performance bonus of up to 30% of his base salary, contingent on individual and corporate objectives. If his employment is terminated without cause, for good reason, or in connection with a change of control, Ervin will receive six months of his final base salary as severance, paid as salary continuation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Thera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3vHHn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"gpt_icon":0},{"id":"2588044174","title":"BRIEF-Allarity Therapeutics Inc - To Offer Up To $50 Million In Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2588044174","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588044174?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:12","pubTimestamp":1764771161,"startTime":"0","endTime":"0","summary":"BRIEF-Allarity Therapeutics Inc - To Offer Up To $50 Million In Securities Dec 3  - Allarity Therapeutics Inc ALLR.O:ALLARITY THERAPEUTICS INC - TO OFFER UP TO $50 MILLION IN SECURITIES - SEC FILINGSource text: [ID:n0001213900-25-117592]Further company coverage: ALLR.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90FG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","BK4139"],"gpt_icon":0},{"id":"2588044126","title":"Allarity Therapeutics Inc - to Offer up to $50 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588044126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588044126?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:12","pubTimestamp":1764771137,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90FG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLR","BK4139"],"gpt_icon":0},{"id":"2583501092","title":"Allarity Therapeutics's Q3 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583501092","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583501092?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:08","pubTimestamp":1763129319,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics's Q3 net loss narrowsOverviewAllarity receives FDA Fast Track designation for stenoparib in advanced ovarian cancerCompany reports median overall survival exceeding 25 months in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLR"],"gpt_icon":0},{"id":"2583501290","title":"Allarity Therapeutics reports third quarter net loss of $2.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583501290","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583501290?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:00","pubTimestamp":1763128814,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Inc. reported a cash position of $16.9 million as of September 30, 2025, a decrease of $0.9 million from June 30, 2025. Research and development expenses for the third quarter of 2025 were $1.2 million, up from $1.0 million in the same period in 2024. General and administrative expenses were $1.3 million, down from $1.6 million in the third quarter of 2024. The net loss attributable to common stockholders was $2.8 million, compared to a net loss of $12.2 million in the third quarter of 2024. Key business developments included receiving FDA Fast Track designation for stenoparib in advanced ovarian cancer, reporting median overall survival now exceeding 25 months in an ongoing Phase 2 trial, and signing a new commercial agreement to license breast cancer DRP algorithms and laboratory services. The company maintains a financial runway through the fourth quarter of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL2jxvym:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","ALLR","IE00B64PRP62.GBP","BK4139","LU0314104364.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2583012885","title":"Allarity Therapeutics Q3 Operating Expenses USD 2.518 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583012885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583012885?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:00","pubTimestamp":1763128803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX11943B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"gpt_icon":0},{"id":"2583233501","title":"Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583233501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583233501?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:00","pubTimestamp":1763128802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA1Z0LN9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"gpt_icon":0},{"id":"2570074698","title":"U.S. RESEARCH ROUNDUP-Carmax, Mirion Technologies, Valmont Industries","url":"https://stock-news.laohu8.com/highlight/detail?id=2570074698","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570074698?lang=en_us&edition=fundamental","pubTime":"2025-09-26 14:53","pubTimestamp":1758869609,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Carmax, Mirion Technologies, Valmont IndustriesSept 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies, includ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nL5N3VD07G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCK","LU2324357040.USD","VMI","LU2168563687.JPY","LU2210149790.SGD","LU0648001328.SGD","LU0965509010.AUD","LU2089279066.USD","BK4007","THO","IMRX","BK4551","LU2168564065.EUR","FHN","LU0265550946.USD","CALM","LU0130102774.USD","IE00BLDYK493.USD","CRNX","LU0980610538.SGD","GH","BK4023","KMX","LU1061106388.HKD","ROL","LU0823434583.USD","LU1116320737.USD","KVYO","LU0234572021.USD","LU0097036916.USD","LEVI","LU1551013425.SGD","LU2125909916.SGD","LU1035775433.USD","LU2125154935.USD","SNX","LU2211817866.USD","MIR","FRME","ALLR","LU0053671581.USD","LU0238689110.USD","LU1983260115.SGD","LU1116320901.HKD"],"gpt_icon":1},{"id":"2570075969","title":"Allarity Therapeutics Inc : Ascendiant Capital Markets Raises Target Price to $9.25 From $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2570075969","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570075969?lang=en_us&edition=fundamental","pubTime":"2025-09-26 13:09","pubTimestamp":1758863360,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nFWN3VD09F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLR"],"gpt_icon":0},{"id":"2570051044","title":"Allarity files to sell 1.56M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2570051044","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570051044?lang=en_us&edition=fundamental","pubTime":"2025-09-26 05:25","pubTimestamp":1758835529,"startTime":"0","endTime":"0","summary":"17:21 EDT Allarity (ALLR) files to sell 1.56M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/allarity-files-to-sell-1-56m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/allarity-files-to-sell-1-56m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALLR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.allarity.com","stockEarnings":[{"period":"1week","weight":0.1085},{"period":"1month","weight":-0.1597},{"period":"3month","weight":-0.2001},{"period":"6month","weight":-0.3507},{"period":"1year","weight":0.4183},{"period":"ytd","weight":-0.0742}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.137955},{"month":2,"riseRate":0,"avgChangeRate":-0.227935},{"month":3,"riseRate":0.25,"avgChangeRate":-0.326601},{"month":4,"riseRate":0.25,"avgChangeRate":-0.371644},{"month":5,"riseRate":0.25,"avgChangeRate":-0.092052},{"month":6,"riseRate":0.25,"avgChangeRate":-0.349039},{"month":7,"riseRate":0.25,"avgChangeRate":-0.205374},{"month":8,"riseRate":0.25,"avgChangeRate":0.045342},{"month":9,"riseRate":0.25,"avgChangeRate":-0.31064},{"month":10,"riseRate":0,"avgChangeRate":-0.290985},{"month":11,"riseRate":0,"avgChangeRate":-0.125579},{"month":12,"riseRate":0.25,"avgChangeRate":-0.118424}],"exchange":"NASDAQ","name":"Allarity Therapeutics Inc","nameEN":"Allarity Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Allarity Therapeutics Inc(ALLR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Allarity Therapeutics Inc,ALLR,Allarity Therapeutics Inc股票,Allarity Therapeutics Inc股票老虎,Allarity Therapeutics Inc股票老虎国际,Allarity Therapeutics Inc行情,Allarity Therapeutics Inc股票行情,Allarity Therapeutics Inc股价,Allarity Therapeutics Inc股市,Allarity Therapeutics Inc股票价格,Allarity Therapeutics Inc股票交易,Allarity Therapeutics Inc股票购买,Allarity Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Allarity Therapeutics Inc(ALLR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction